title: [Evaluation of bactericidal activity of cefpirome-aminoglycoside combination against Pseudomonas aeruginosa strains with intermediate sensitivity to cefpirome and in various phenotypes of beta-lactam resistance].
abstract: The bactericidal activity of cefpirome (CPO)-aminoglycoside (AG) combination was assessed by a kinetic time-kill method against 8 strains of Pseudomonas aeruginosa showing intermediate susceptibility to cefpirome (MICS: 8-32 mg/l). Six strains had an acquired beta-lactam resistance mechanism (moderate cephalosporinase hyperproduction, OXA-2 or PSE-1 enzyme production, non enzymatic resistance) and one strain was resistant to tobramycin (TOB). Antibiotic concentrations used for time-kill curves were 1/2, 1 and 2x MIC for cefpirome, 8 mg/l for tobramycin and 16 mg/l for amikacin (AKN). Bactericidal activity was defined as a (4 log10 reduction of the initial inoculum. At the concentrations used in this study, CPO was not bactericidal; AG were bactericidal in 3 to 24 hours. CPO-AG combination was bactericidal against all the strains with no secondary regrowth. For 7/8 strains, the combination of CPO with TOB and/or AKN was more rapidly bactericidal than the AG alone. In conclusion, despite an intermediate susceptibility against numerous strains of P. aeruginosa, the CPO-AG combination is bactericidal at concentrations achievable with standard dosing regimens in man.
authors.affiliation: Laboratoire de Bactériologie-Hygiène, Faculté de Médecine, Lille, France.
authors.forename: F
authors.initials: F
authors.lastname: Canis
authors.forename: J D
authors.initials: JD
authors.lastname: Cavallo
authors.forename: M O
authors.initials: MO
authors.lastname: Husson
mesh_terms: D000583:Amikacin / Q000008:administration & dosage / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002511:Cephalosporins / Q000008:administration & dosage / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination / Q000494:pharmacology*; D066298:In Vitro Techniques; D008826:Microbial Sensitivity Tests; D010641:Phenotype; D011550:Pseudomonas aeruginosa / Q000145:classification / Q000187:drug effects* / Q000235:genetics; D014031:Tobramycin / Q000008:administration & dosage / Q000494:pharmacology; D000097572:Cefpirome
chemical_list: D000583:Amikacin; D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D014031:Tobramycin; D000097572:Cefpirome